Park City Bio LLC has prepared and tested new serotonin receptor agonists reported to be useful for the treatment of pain, inflammation, psychiatric and neurological disorders.
Do men’s and women’s brains age equally? Women are more often diagnosed with Alzheimer’s disease (AD) than men. Age is the primary known risk factor for AD prevalence, and both aging and AD are associated with brain atrophy, but it is still not clear whether men and women differ regarding brain decline in aging.
Solu Therapeutics Inc. has identified heterobifunctional cotinine-containing compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers or sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers. They are reported to be useful for the treatment of pain, cough and pruritus.
Nippon Shinyaku Co. Ltd. has disclosed compounds inhibiting binding between r(CUG) repeats in DMPK (DM1) and MBNL protein reported to be useful for the treatment of myotonic dystrophy 1.
Positive allosteric modulators (PAMs) of the muscarinic acetylcholine M4 receptor show potential against schizophrenia because they can enhance endogenous acetylcholine signaling, which in turn may mitigate psychotic symptoms as well as improve attention and working memory in individuals with the disorder. However, the efficacy of a promising PAM, CVL-231, has been disappointing in clinical trials.
SK Biopharmaceuticals Co. Ltd. and Eurofarma Laboratórios SA launched a new joint venture (JV) called Mentis Care Inc. Oct. 21, dedicated to developing an AI-powered platform for epilepsy management.
The U.K’s Engineering and Physical Sciences Research Council provided the University of Oxford with £11 million (US$ 14.7 million) in research funding to develop technologies that will reduce or eliminate chronic pain.
Interim results from the PRIMAVERA study published in the New England Journal of Medicine demonstrated that Science Corp.'s Prima retinal implant restored vision, enabling 80% of patients to read at 12 months. Participants had age-related macular degeneration-related geographic atrophy resulting in total loss of central vision.
The failure of Alector Inc.’s phase III study of latozinemab in treating dementia halved the company’s stock on Oct. 22. That is also about the same percentage of staff that Alector is letting go after the clinical trial stumble.
Having reached peace with Jazz Pharmaceuticals plc over litigation related to its U.S. FDA-approved drug, Lumryz (sodium oxybate), Avadel Pharmaceuticals plc agreed to a cash takeover by Alkermes plc valued at about $2.1 billion, a deal Alkermes CEO Richard Pops said “puts us in the sleep market immediately on closing,” which is expected in the first quarter of 2026. All three players are based in Dublin.
RSS
